Spiradine FCAS# 21040-64-2 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 21040-64-2 | SDF | Download SDF |
| PubChem ID | 91895271 | Appearance | Powder |
| Formula | C24H33NO4 | M.Wt | 399.5 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [(1S,2R,5S,7R,8R,12R,13S,20S,21R)-12-methyl-4-methylidene-14,19-dioxa-17-azaheptacyclo[10.7.2.22,5.02,7.08,18.08,21.013,17]tricosan-20-yl] acetate | ||
| SMILES | CC(=O)OC1C2C3(CCCC24C5CC6CCC5(C1OC4N7C3OCC7)CC6=C)C | ||
| Standard InChIKey | HSZMQRORNAEJTB-YBUCERMMSA-N | ||
| Standard InChI | InChI=1S/C24H33NO4/c1-13-12-23-8-5-15(13)11-16(23)24-7-4-6-22(3)18(24)17(28-14(2)26)19(23)29-21(24)25-9-10-27-20(22)25/h15-21H,1,4-12H2,2-3H3/t15-,16+,17-,18+,19+,20-,21?,22+,23+,24+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Spiradine F can significantly inhibit platelet-activating factor(PAF)-induced platelet aggregation in a concentration-dependent manner. |
| Targets | PAFR |
Spiradine F Dilution Calculator
Spiradine F Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5031 mL | 12.5156 mL | 25.0313 mL | 50.0626 mL | 62.5782 mL |
| 5 mM | 0.5006 mL | 2.5031 mL | 5.0063 mL | 10.0125 mL | 12.5156 mL |
| 10 mM | 0.2503 mL | 1.2516 mL | 2.5031 mL | 5.0063 mL | 6.2578 mL |
| 50 mM | 0.0501 mL | 0.2503 mL | 0.5006 mL | 1.0013 mL | 1.2516 mL |
| 100 mM | 0.025 mL | 0.1252 mL | 0.2503 mL | 0.5006 mL | 0.6258 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Cinnamyl acetate
Catalog No.:BCN4914
CAS No.:21040-45-9
- Z-LEHD-FMK
Catalog No.:BCC5117
CAS No.:210345-04-3
- Ac-LEHD-AFC
Catalog No.:BCC2359
CAS No.:210345-03-2
- Z-WEHD-FMK
Catalog No.:BCC1139
CAS No.:210345-00-9
- Z-IETD-FMK
Catalog No.:BCC5116
CAS No.:210344-98-2
- Z-DEVD-FMK
Catalog No.:BCC1137
CAS No.:210344-95-9
- Gallein
Catalog No.:BCC7563
CAS No.:2103-64-2
- 7-Hydroxycadalene
Catalog No.:BCN7501
CAS No.:2102-75-2
- 6-Formyl-1,2,9,10-tetramethoxy-6a,7-dehydroaporphine
Catalog No.:BCN6436
CAS No.:2101836-45-5
- Amarogentin
Catalog No.:BCN2661
CAS No.:21018-84-8
- Miglustat hydrochloride
Catalog No.:BCC5186
CAS No.:210110-90-0
- 5,8,9,10,14-Pentaacetoxy-3-benzoyloxy-15-hydroxypepluane
Catalog No.:BCN1498
CAS No.:210108-91-1
- Odoratin-7-O-beta-D-glucopyranoside
Catalog No.:BCN8089
CAS No.:210413-47-1
- Sitaxentan sodium
Catalog No.:BCC4495
CAS No.:210421-74-2
- 1,11b-Dihydro-11b-hydroxymedicarpin
Catalog No.:BCN3913
CAS No.:210537-04-5
- 1,11b-Dihydro-11b-hydroxymaackiain
Catalog No.:BCN3914
CAS No.:210537-05-6
- 6alpha-Hydroxylycopodine
Catalog No.:BCN7403
CAS No.:21061-92-7
- PD 168568 dihydrochloride
Catalog No.:BCC7702
CAS No.:210688-56-5
- 5,7-Dihydroxy-4-Methylcoumarin
Catalog No.:BCC8284
CAS No.:2107-76-8
- 7,8-Dihydroxy-4-Methylcoumarin
Catalog No.:BCC8290
CAS No.:2107-77-9
- CP 471474
Catalog No.:BCC2373
CAS No.:210755-45-6
- Sakakin
Catalog No.:BCN4916
CAS No.:21082-33-7
- Org 12962 hydrochloride
Catalog No.:BCC7718
CAS No.:210821-63-9
- W-84 dibromide
Catalog No.:BCC6682
CAS No.:21093-51-6
Antiplatelet aggregation activity of diterpene alkaloids from Spiraea japonica.[Pubmed:12163102]
Eur J Pharmacol. 2002 Aug 2;449(1-2):23-8.
Six diterpene alkaloids with an atisine-type C(20)-skeleton isolated from the Chinese herbal medicines Spiraea japonica var. acuta and S. japonica var. ovalifolia, as well as eight derivatives of spiramine C and Spiradine F were evaluated for the ability to inhibit aggregation of rabbit platelets induced by arachidonic acid, ADP, and platelet-activating factor (PAF) in vitro. The results showed that 12 of the 14 atisine-type diterpene alkaloids significantly inhibited PAF-induced platelet aggregation in a concentration-dependent manner, but had no effect on ADP- or arachidonic acid-induced aggregation, exhibiting a selective inhibition. It is the first report that C(20)-diterpene alkaloids inhibit PAF-induced platelet aggregation. However, spiramine C1 concentration-dependently inhibited platelet aggregation induced by PAF, ADP and arachidonic acid with IC(50) values of 30.5+/-2.7, 56.8+/-8.4 and 29.9+/-9.9 microM, respectively, suggesting a non-selective antiplatelet aggregation action. The inhibitory effect of spiramine C1 on arachidonic acid was as potent as that of aspirin. Primary studies of the structure-activity relationships for inhibition of PAF-induced aggregation showed that the oxygen substitution at the C-15 position and the presence of an oxazolidine ring in spiramine alkaloids were essential to their antiplatelet aggregation effects. These results suggest that the atisine-type alkaloids isolated from S. japonica are a class of novel antiplatelet aggregation agents.
